BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 38526540)

  • 1. Metastatic colorectal cancer- third line therapy and beyond.
    Foo T; Roy A; Karapetis C; Townsend A; Price T
    Expert Rev Anticancer Ther; 2024 May; 24(5):219-227. PubMed ID: 38526540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted drugs for metastatic colorectal cancer.
    Cheng YD; Yang H; Chen GQ; Zhang ZC
    Drug Des Devel Ther; 2013; 7():1315-22. PubMed ID: 24204124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.
    Lau DK; Burge M; Roy A; Chau I; Haller DG; Shapiro JD; Peeters M; Pavlakis N; Karapetis CS; Tebbutt NC; Segelov E; Price TJ
    Expert Rev Anticancer Ther; 2020 Apr; 20(4):251-270. PubMed ID: 32186929
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel therapeutics in metastatic colorectal cancer: molecular insights and pharmacogenomic implications.
    Hanna DL; Lenz HJ
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1091-108. PubMed ID: 27031164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
    Davis LE
    Am J Manag Care; 2018 Apr; 24(7 Suppl):S107-S117. PubMed ID: 30207665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing face of treatment for metastatic colorectal cancer.
    Pfeiffer P; Köhne CH; Qvortrup C
    Expert Rev Anticancer Ther; 2019 Jan; 19(1):61-70. PubMed ID: 30381969
    [No Abstract]   [Full Text] [Related]  

  • 8. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer.
    Baek SK; Lee KT; Bae SB; Lee SC
    Korean J Intern Med; 2019 Nov; 34(6):1188-1196. PubMed ID: 31346151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic treatment for metastatic colorectal cancer in the era of precision medicine.
    Sandhu J; Lavingia V; Fakih M
    J Surg Oncol; 2019 Apr; 119(5):564-582. PubMed ID: 30802315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalizing medicine for metastatic colorectal cancer: current developments.
    Marques AM; Turner A; de Mello RA
    World J Gastroenterol; 2014 Aug; 20(30):10425-31. PubMed ID: 25132758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for metastatic colorectal cancer.
    Price TJ; Tang M; Gibbs P; Haller DG; Peeters M; Arnold D; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M; Shapiro J
    Expert Rev Anticancer Ther; 2018 Oct; 18(10):991-1006. PubMed ID: 30019590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of targeted agents in metastatic colorectal cancer.
    Prenen H; Vecchione L; Van Cutsem E
    Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer.
    Lee YC; Michael M; Zalcberg JR
    Expert Opin Investig Drugs; 2015; 24(10):1307-20. PubMed ID: 26212373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A decade of progress: advances in the third-line treatment of patients with metastatic colorectal cancer.
    Bekaii-Saab T
    Am J Manag Care; 2024 May; 30(2 Suppl):S23-S30. PubMed ID: 38701363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic colorectal cancer: current state and future directions.
    Fakih MG
    J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients.
    Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M
    Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396
    [No Abstract]   [Full Text] [Related]  

  • 18. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer.
    Kim SY; Kim TW
    ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment sequencing in metastatic colorectal cancer.
    Modest DP; Pant S; Sartore-Bianchi A
    Eur J Cancer; 2019 Mar; 109():70-83. PubMed ID: 30690295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
    Heinemann V; Stintzing S; Modest DP; Giessen-Jung C; Michl M; Mansmann UR
    Eur J Cancer; 2015 Sep; 51(14):1927-36. PubMed ID: 26188850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.